HSP90AA1 and lupus erythematosus: One Studie suggests that HSP90AA1, as a glucocorticoid receptor chaperone, can affect the efficacy of glucocorticoid therapy in lupus erythematosus, potentially playing a similar role in AD patients.[54] Additionally, inhibition of HSP90AA1 has been found to alleviate inflammation in AD models, which indicating that HSP90AA1 inhibition may offer a novel therapeutic mechanism for AD.[46,55] EGFR, a crucial epidermal growth factor receptor, stimulates epidermal cell proliferation and inhibits their differentiation.